5-OH-DPAT - Misplaced Pages

Dopamine receptor agonist compound

5-OH-DPAT
Names

Preferred IUPAC name (6S)-6-(Dipropylamino)-5,6,7,8-tetrahydronaphthalen-1-ol
Identifiers
CAS Number	68593-96-4
3D model (JSmol)	Interactive image Interactive image Interactive image
Abbreviations	5-OH-DPAT
ChEMBL	ChEMBL273273
ChemSpider	9474597 (S) 150564
MeSH	5-Hydroxy-2-N,N-dipropylaminotetralin
PubChem CID	11299620 (S) 12280580 (R) 172267
CompTox Dashboard (EPA)	DTXSID801336109
InChI InChI=1S/C16H25NO/c1-3-10-17(11-4-2)14-8-9-15-13(12-14)6-5-7-16(15)18/h5-7,14,18H,3-4,8-12H2,1-2H3/t14-/m0/s1Key: MDBWEQVKJDMEMK-AWEZNQCLSA-N
SMILES Oc1cccc2c1CC(N(CCC)CCC)C2 CCCN(CCC)C1CCc2c(O)cccc2C1 CCCN(CCC)C1CCC2=C(O)C=CC=C2C1
Properties
Chemical formula	C₁₆H₂₅NO
Molar mass	247.382 g·mol
log P	3.55
Acidity (pK_a)	10.543
Basicity (pK_b)	3.454
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa). N verify (what is ?) Infobox references

Chemical compound

5-OH-DPAT is a synthetic compound that acts as a dopamine receptor agonist with selectivity for the D₂ receptor and D₃ receptor subtypes. Only the (S)-enantiomer is active as an agonist, with the (R)-enantiomer being a weak antagonist at D₂ receptors. Radiolabelled C-5-OH-DPAT is used as an agonist radioligand for mapping the distribution and function of D₂ and D₃ receptors in the brain, and the drug is also being studied in the treatment of Parkinson's disease.

References

Seiler MP, Stoll AP, Closse A, Frick W, Jaton A, Vigouret JM (June 1986). "Structure-activity relationships of dopaminergic 5-hydroxy-2-aminotetralin derivatives with functionalized N-alkyl substituents". Journal of Medicinal Chemistry. 29 (6): 912–7. doi:10.1021/jm00156a007. PMID 3712381.
Johansson AM, Nilsson JL, Karlén A, Hacksell U, Svensson K, Carlsson A, Kenne L, Sundell S (July 1987). "C3-methylated 5-hydroxy-2-(dipropylamino)tetralins: conformational and steric parameters of importance for central dopamine receptor activation". Journal of Medicinal Chemistry. 30 (7): 1135–44. doi:10.1021/jm00390a004. PMID 3599021.
Karlsson A, Björk L, Pettersson C, Andén NE, Hacksell U (1990). "(R)- and (S)-5-hydroxy-2-(dipropylamino)tetralin (5-OH DPAT): assessment of optical purities and dopaminergic activities". Chirality. 2 (2): 90–5. doi:10.1002/chir.530020206. PMID 1976017.
Mukherjee J, Narayanan TK, Christian BT, Shi B, Dunigan KA, Mantil J (July 2000). "In vitro and in vivo evaluation of the binding of the dopamine D2 receptor agonist (11)C-(R,S)-5-hydroxy-2-(di-n-propylamino)tetralin in rodents and nonhuman primate". Synapse (New York, N.Y.). 37 (1): 64–70. doi:10.1002/(SICI)1098-2396(200007)37:1<64::AID-SYN7>3.0.CO;2-F. PMID 10842352. S2CID 43878278.
Leung K (2006). "(R,S)-2-(N-Propyl-N-1'--propyl)amino-5-hydroxytetralin". Molecular Imaging and Contrast Agent Database (MICAD) . Bethesda (MD): National Center for Biotechnology Information (US). PMID 20641325.
Ackaert OW, Graan JD, Shi S, Vreeken R, Della Pasqua OE, Dijkstra D, Westerink BH, Danhof M, Bouwstra JA (January 2011). "The pharmacokinetics and pharmacological effect of (S)-5-OH-DPAT following controlled delivery with transdermal iontophoresis". Journal of Pharmaceutical Sciences. 100 (7): 2996–3009. doi:10.1002/jps.22492. PMID 21283984.